Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Urology
Poster (digital)
Clinical
Organ preservation with tri-modality in bladder Ca- Experience from a Cancer institute in LMIC
Muneeb Uddin Karim, Pakistan
PO-1386

Abstract

Organ preservation with tri-modality in bladder Ca- Experience from a Cancer institute in LMIC
Authors:

Muneeb Uddin Karim1, Aqueel Shahid2, Maryam Inayat2, Muhammad Atif Mansha2, Taskheer Abbas2, Sumera Butt2

1Shaukat Khanum Memorial Cancer Hospital & Research Centre , Clinical & Radiation Oncology, Lahore, Pakistan; 2Shaukat Khanum Memorial Cancer Hospital & Research Centre, Clinical & Radiation Oncology, Lahore, Pakistan

Show Affiliations
Purpose or Objective

Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is the gold standard for the treatment of muscle-invasive bladder Ca. However, the gold standard may not be the best treatment for individual patients. The alternative best treatment option is the bladder sparing tri-modality treatment in which surgery (maximal TURBT) is followed by definitive chemoradiation therapy with the intent of cure along with organ preservation.

Our primary objective includes the estimation of the overall survival and disease-free survival at 3 and 5 years in patients of bladder cancer treated with a bladder preservation approach at a dedicated cancer institute. Secondary objectives include the outcome of different radiation fractionation, induction chemotherapy and time to radiation after TURBT.

Material and Methods

After taking IRB approval, 91 patients of bladder cancer treated with curative intent and bladder preservation approach, between January 2010 till December 2018 were retrospectively reviewed. Demographic characteristics and details of all procedures including surgery (TURBT), chemotherapy and radiation therapy were documented with the help of the Hospital Information System. Treatment response and follow-up details were documented according to notes.   

Results

The median age was 63 (range 28-84). 89% (n=80) were male. Out of 91 patients, 53 (58%) patients had T3 disease and 32 (35%) of the patients had node-positive disease. Induction chemotherapy was given in 43 patients (47.3 %) after TURBT. 78 (85.7%) patients received concurrent chemotherapy with radiation therapy. Hypo-fractionated radiation therapy (55Gy in 20 fractions) was given in 50 patients (54.9%). Overall survival was found to be 77% and 62% and DFS was 62% and 51% at 3 and 5 years respectively. Induction chemotherapy had no significant impact on OS. However, OS was estimated to be higher in those patients in which radiation therapy was started within 6 weeks of TURBT and in those patients who received hypofractionated radiotherapy.


Conclusion

Our study shows that bladder preservation therapy is an effective approach that can be the best treatment in selected patients with Bladder Ca.  Overall survival at 3 and 5 years in patients treated with bladder preservation approach at our institute is comparable to the standard of care (radical cystectomy). We recommend case discussion in a Multidisciplinary site-specific tumour board which is important and necessary for offering organ preservation to the bladder ca patients.